IP Library › Granted Patent US 11,377,640
Granted Patent B2
US 11,377,640 · App. 16/435,428 · Granted Jul 5, 2022

Differentiation of human embryonic stem cells into single hormonal insulin positive cells

Inventor: Alireza Rezania (Wellesley, MA)
Assignee: Janssen Biotech, Inc.
C12N5/0676C12N2500/34C12N2500/38C12N2501/117C12N2501/15C12N2501/155C12N2501/16C12N2501/19C12N2501/385C12N2501/41C12N2501/415C12N2501/727C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,377,640
App. No.
16/435,428
Granted
Jul 5, 2022
Kind
B2
Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.

Claims (20)

1. An in vitro method for the stepwise differentiation of pluripotent cells into a population of cells comprising pancreatic endocrine cells, comprising:

differentiating the pluripotent cells into foregut endoderm cells; and

differentiating the foregut endoderm cells in a first medium supplemented with retinoic acid, ascorbic acid, a shh inhibitor and a BMP inhibitor, thereby producing the population of cells comprising the pancreatic endocrine cells.

2. The in vitro method of claim 1 , wherein the shh inhibitor is SANT-1.

3. The in vitro method of claim 1 , wherein the BMP inhibitor is LDN-193189 or Noggin.

4. The in vitro method of claim 1 , wherein differentiating the foregut endoderm cells in the first medium supplemented with retinoic acid, ascorbic acid, the shh inhibitor and the BMP inhibitor produces foregut precursor cells, and wherein the method further comprises:

differentiating the foregut precursor cells in a second medium supplemented with a shh inhibitor.

5. The in vitro method of claim 4 , wherein the second medium is further supplemented with a BMP inhibitor.

6. The in vitro method of claim 5 , wherein the BMP inhibitor is LDN-193189 or Noggin.

7. The in vitro method of claim 4 , wherein the second medium is further supplemented with an ALK5 inhibitor.

8. The in vitro method of claim 4 , wherein the shh inhibitor in the second medium is SANT-1.

9. The in vitro method of claim 4 , wherein the second medium is further supplemented with retinoic acid.

10. The in vitro method of claim 4 , wherein the second medium is further supplemented with ascorbic acid.

11. The in vitro method of claim 4 , wherein the second medium further comprises a BMP inhibitor, and wherein differentiating the foregut precursor cells in the second medium supplemented with the shh inhibitor and the BMP inhibitor produces pancreatic endoderm cells and pancreatic endocrine precursor cells, and wherein the method further comprises:

differentiating the pancreatic endoderm cells and the pancreatic endocrine precursor cells to form pancreatic endocrine cells in a third medium supplemented with a shh inhibitor.

12. The in vitro method of claim 11 , wherein the shh inhibitor in the second medium is SANT-1.

13. The in vitro method of claim 11 , wherein the third medium is further supplemented with retinoic acid.

14. The in vitro method of claim 11 , wherein the third medium is further supplemented with ascorbic acid.

15. The in vitro method of claim 11 , wherein the third medium is further supplemented with an ALK5 inhibitor.

16. The in vitro method of claim 1 , wherein the pancreatic endocrine cells are single hormonal insulin-producing cells which are also NKX6.1+ and PDX-1+.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2022
From: REZANIA, ALIREZA
To: JANSSEN BIOTECH, INC.
Reel/Frame 058545/0028 →
Continuity (4)
Continuation 14831115 · Aug 20, 2015
Division 13708369 · Dec 7, 2012
Provisional Application 61579351 · Dec 22, 2011
Related Publication 20190292523A1 · Sep 26, 2019